These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 29191856)

  • 21. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
    Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
    J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 24. A novel PSMA targeted dual-function near-infrared fluorescence and PET probe for the image-guided surgery and detection of prostate cancer.
    Fu H; Lou K; He H; Wang Y; Mi Y; Li W; Chen L; Zhang Y; Yu C
    Eur J Nucl Med Mol Imaging; 2024 Aug; 51(10):2998-3008. PubMed ID: 37914976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
    Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated
    Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
    Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving the Imaging Contrast of
    Baranski AC; Schäfer M; Bauder-Wüst U; Wacker A; Schmidt J; Liolios C; Mier W; Haberkorn U; Eisenhut M; Kopka K; Eder M
    Bioconjug Chem; 2017 Sep; 28(9):2485-2492. PubMed ID: 28787147
    [No Abstract]   [Full Text] [Related]  

  • 28. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
    Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
    Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [
    Berliner C; Tienken M; Frenzel T; Kobayashi Y; Helberg A; Kirchner U; Klutmann S; Beyersdorff D; Budäus L; Wester HJ; Mester J; Bannas P
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):670-677. PubMed ID: 27896369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.
    Giesel FL; Fiedler H; Stefanova M; Sterzing F; Rius M; Kopka K; Moltz JH; Afshar-Oromieh A; Choyke PL; Haberkorn U; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1794-800. PubMed ID: 26162799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Accuracy of Multiparametric MRI versus
    Muehlematter UJ; Burger IA; Becker AS; Schawkat K; Hötker AM; Reiner CS; Müller J; Rupp NJ; Rüschoff JH; Eberli D; Donati OF
    Radiology; 2019 Nov; 293(2):350-358. PubMed ID: 31502937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiochemistry and Preclinical PET Imaging of
    Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
    Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
    Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
    J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Early and Late [
    Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
    Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
    Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.